Home › Funds › T. Rowe Price › T. Rowe Price Health Sciences Portfolio
Fund family: T. Rowe Price · Filed by T. Rowe Price Equity Series, Inc. (CIK 918294) · SEC series S000002083
Share classes and tickers: QAAGZX (C000005448), QAAHBX (C000005449)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,345 with, 27 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as T. Rowe Price’s manager page (244,024 ballot items across 112 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | T. Rowe Price | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.4% | 1,280 | 93.7% | 208,710 |
| Backed environmental and social shareholder proposals at US companies | n/a | 8 | 2.6% | 3,333 |
Each ballot item this fund voted is set against the votes of the other T. Rowe Price funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most T. Rowe Price funds on 11 items (1.1% of the 1,043 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most T. Rowe Price funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Shattuck Labs, Inc. | 2026-05-28 | To approve an amendment and restatement of the Company's 2020 Equity Incentive Plan. | Against | FOR — 8 of 8 T. Rowe Price funds | Against | Passed (calculated), 80.2% support |
| Immatics N.V. | 2026-06-18 | Approve 2026 Stock Option and Incentive Plan | Against | FOR — 8 of 8 T. Rowe Price funds | Against | — |
| Immatics N.V. | 2026-06-18 | Reelect A.L. Stone as Non-Executive Director III | For | AGAINST — 8 of 8 T. Rowe Price funds | For | — |
| Cytokinetics, Incorporated | 2026-05-27 | 2 wordings Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D. | Withhold | FOR — 15 of 21 T. Rowe Price funds | Against | Passed (calculated), 97.0% support |
| Molina Healthcare, Inc. | 2026-05-06 | To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. | For | AGAINST — 11 of 16 T. Rowe Price funds | For | Passed (calculated), 52.8% support |
| MapLight Therapeutics, Inc. | 2026-06-23 | To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Martin Babler | For | WITHHOLD — 8 of 13 T. Rowe Price funds | For | — |
| Xenon Pharmaceuticals Inc. | 2026-06-02 | To approve the Corporation's 2026 Equity Incentive Plan; | Against | FOR — 7 of 11 T. Rowe Price funds | Against | Approved, 68.0% support |
| Kodiak Sciences Inc. | 2026-06-02 | Elect three Class II directors nominated by our board and named in this proxy statement: Charles A. Bancroft | For | WITHHOLD — 8 of 14 T. Rowe Price funds | For | Elected, 78.7% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: David Schenkein, M.D. | For | WITHHOLD — 8 of 14 T. Rowe Price funds | For | Elected, 73.5% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: Jennifer Cook | For | WITHHOLD — 8 of 14 T. Rowe Price funds | For | Elected, 60.9% support |
| Dianthus Therapeutics, Inc. | 2026-05-21 | To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge | For | WITHHOLD — 8 of 15 T. Rowe Price funds | For | Passed (calculated), 80.6% support |
Download all 11 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 77.5% of this fund’s 1,372 such votes could be given a sector; the other 309 (22.5%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 997 | 23 | 2.3% |
| Industrials | 49 | 2 | 4.1% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 807 | 0 |
| Audit-related | 159 | 0 |
| Say-on-Pay | 140 | 0 |
| Compensation | 107 | 2 |
| Capital Structure | 84 | 0 |
| Corporate Governance | 74 | 16 |
| Other Social Issues | 7 | 5 |
| Shareholder Rights and Defenses | 7 | 1 |
| Extraordinary Transactions | 4 | 0 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $114M | 10 | 2 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $39M | 13 | 0 |
| argenx SE | November 18, 2025 | $37M | 1 | 0 |
| UnitedHealth Group Incorporated | June 1, 2026 | $31M | 12 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $28M | 18 | 3 |
| AbbVie Inc. | May 8, 2026 | $27M | 8 | 1 |
| argenx SE | May 6, 2026 | $26M | 12 | 0 |
| Intuitive Surgical, Inc. | April 30, 2026 | $24M | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 13, 2026 | Elevance Health, Inc. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | Against | For |
These funds reported the same votes as T. Rowe Price Health Sciences Portfolio in the latest season, so they share this page:
1,392 ballot items at 160 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, T. Rowe Price Health Sciences Portfolio (QAAGZX) voted at 160 shareholder meetings of 156 companies, on 1,392 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 27 times. Its most frequent area of disagreement was corporate governance (16 of its votes against management). It voted on 26 shareholder proposals. It voted FOR the board's own proposals less often than T. Rowe Price's funds as a whole (92.4% against 93.7%). It voted differently from most T. Rowe Price funds on 11 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of T. Rowe Price’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.